Decibel Therapeutics Inc.

2.65+0.4100+18.30%Vol 494.28K1Y Perf -74.43%
Jun 28th, 2022 16:00 DELAYED
BID2.60 ASK2.89
Open2.50 Previous Close2.24
Pre-Market- After-Market2.66
 - -  0.01 0.38%
Target Price
18.25 
Analyst Rating
Strong Buy 1.00
Potential %
588.68 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
10.35 
Earnings Rating
Market Cap66.15M 
Earnings Date
9th Aug 2022
Alpha-0.12 Standard Deviation0.16
Beta0.39 

Today's Price Range

2.492.89

52W Range

1.839.75

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-3.45%
1 Month
-4.27%
3 Months
-25.08%
6 Months
-54.10%
1 Year
-74.43%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DBTX2.650.410018.30
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.54-0.56-3.70
Q04 2021-0.41-0.49-19.51
Q03 2021-0.40-0.66-65.00
Q02 2021-0.39-0.47-20.51
Q01 2021-0.38-1.09-186.84
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.54
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume494.28K
Shares Outstanding24.96K
Shares Float15.66M
Trades Count2.03K
Dollar Volume1.36M
Avg. Volume60.41K
Avg. Weekly Volume50.90K
Avg. Monthly Volume63.34K
Avg. Quarterly Volume66.98K

Decibel Therapeutics Inc. (NASDAQ: DBTX) stock closed at 2.24 per share at the end of the most recent trading day (a -10.04% change compared to the prior day closing price) with a volume of 54.82K shares and market capitalization of 66.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 37 people. Decibel Therapeutics Inc. CEO is Laurence E. Reid.

The one-year performance of Decibel Therapeutics Inc. stock is -74.43%, while year-to-date (YTD) performance is -51.83%. DBTX stock has a five-year performance of %. Its 52-week range is between 1.8306 and 9.75, which gives DBTX stock a 52-week price range ratio of 10.35%

Decibel Therapeutics Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.49, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -28.86%, a ROC of -32.71% and a ROE of -35.65%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Decibel Therapeutics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. Decibel Therapeutics Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Decibel Therapeutics Inc. is Strong Buy (1), with a target price of $18.25, which is +588.68% compared to the current price. The earnings rating for Decibel Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Decibel Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Decibel Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.68, ATR14 : 0.25, CCI20 : -75.97, Chaikin Money Flow : -0.06, MACD : 0.00, Money Flow Index : 50.79, ROC : -16.57, RSI : 45.17, STOCH (14,3) : 8.75, STOCH RSI : 0.00, UO : 37.65, Williams %R : -91.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Decibel Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Decibel Therapeutics Inc.

Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear.

CEO: Laurence E. Reid

Telephone: +1 617 370-8701

Address: 1325 Boylston Street, Boston 02215, MA, US

Number of employees: 37

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

51%49%

Bearish Bullish

52%48%

TipRanks News for DBTX

Thu, 09 Jun 2022 10:16 GMT Decibel Therapeutics (DBTX) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Sat, 14 May 2022 06:15 GMT Analysts Top Healthcare Picks: Decibel Therapeutics (DBTX), Mereo Biopharma Group Plc (MREO)

- TipRanks. All rights reserved.

Fri, 08 Apr 2022 03:36 GMT Decibel Therapeutics (DBTX) Receives a Buy from Robert W. Baird

- TipRanks. All rights reserved.

News

Stocktwits